News
Vivoryon Therapeutics NV to Report Q1 2024 Financial Results and Operating Progress on May 23, 2024
Vivoryon Therapeutics NV
Vivoryon Therapeutics NV to Report Q1 2024 Financial Results and Operating Progress on May 23, 2024
Halle (Saale) / Munich, Germany, May 15, 2024 – Vivoryon Therapeutics NV (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage company focused on the discovery and development of small molecule drugs to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its first quarter financial results for the period ending March 31, 2024 and provide a corporate report update on Thursday, May 23, 2024. The Company will hold a conference call and webcast open to the public.
Conference call details
Date: May 23, 2024
Time: 3pm CEST / 9am EDT
The conference call will be available via telephone and webcast.
The live audio webcast of the conference call will be available on the Vivoryon website at: https://www.vivoryon.com/investors-news/news-and-events/presentations-webcasts/
To participate in the conference call via telephone, participants can pre-register and will receive dedicated dial-in details to access the conference call quickly and easily via the following website:
https://register.vevent.com/register/BI9aadfa99e014435493eca917a11150f1
It is suggested that participants call into the conference call 15 minutes before the scheduled start time to avoid delays in attendance.
###
About Vivoryon Therapeutics NV
Vivoryon is a clinical-stage biotechnology company focused on developing innovative medicines based on small molecules. Driven by its passion for groundbreaking science and innovation, the Company strives to change the lives of patients in need suffering from serious illnesses. The Company leverages its deep expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins that are altered in disease settings. The company has established a pipeline of orally available small molecule inhibitors for a variety of indications, including Alzheimer’s disease, inflammatory and fibrotic disorders, including kidney, and cancer. www.vivoryon.com.
Vivoryon Forward-Looking Statements
This press release includes forward-looking statements, including, without limitation, those relating to Vivoryon Therapeutics NV’s (the “Company”) business strategy, management plans and objectives for future operations, estimates and projections regarding the market for Vivoryon Therapeutics NV’s products. Company. and forecasts and statements about when the Company’s products may be available. Words like “anticipate,” “believe,” “estimate,” “expect,” “predict,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will ” and similar expressions relating to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather, they are based on Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. Forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors may materially and adversely affect the results and financial effects of the plans and events described here. The Company’s results of operations, cash requirements, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied by such forward-looking statements and expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the Company’s published annual financial statements. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company undertakes no obligation to update any forward-looking information or statements contained herein, except for any information required to be disclosed by law.
The story continues
For more information please contact:
Contact with investors
Vivoryon Therapeutics NV
Dr. Manuela Bader, Director of IR and Communication
Tel: +49 (0)345 555 99 30
Email: IR@vivoryon.com
Media contact
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email: vivoryon@tropic.eu
